

Election/Restriction Remarks

Claims 1-8 are pending in the application and are subject to restriction and/or election requirement. Restriction to one of the following invention was required under 35 U.S.C. § 121 and § 372 as follows:

Group I, claim(s) in part 1-8, drawn to A method of vaccinating an individual where an imidazo[4,5-c]quinolin-4-amine is represented by compounds of formula (I).

Group II, claim(s) in part 1-8, drawn to A method of vaccinating an individual where an imidazo[4,5-c]quinolin-4-amine is represented by compounds of formula (II).

Group III, claim(s) in part 1-8, drawn to A method of vaccinating an individual where an imidazo[4,5-c]quinolin-4-amine is represented by compounds of formula (III).

Group IV, claim(s) in part 1-8, drawn to A method of vaccinating an individual where an imidazo[4,5-c]quinolin-4-amine is represented by compounds of formula (IV).


Group V, claim(s) in part 1-8, drawn to A method of vaccinating an individual where an imidazo[4,5-c]quinolin-4-amine is represented by compounds of formula (V).

Group VI, claim(s) in part 1-8, drawn to A method of vaccinating an individual where an imidazo[4,5-c]quinolin-4-amine is represented by compounds of formula (VI).

Upon review of the Detailed Action provided by the Examiner, Applicants provisionally elect the subject matter of Group VI. Upon electing Group VI, Applicants amended claim 8 to prosecute only the elected group.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned agent at the number below

Respectfully submitted,



William T Han
Attorney for Applicants
Registration No. 34,344

GlaxoSmithKline Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5263
Facsimile (610) 270-5090